中国医院用药评价与分析2024，Vol.24Issue(6)：714-716,721,4.DOI:10.14009/j.issn.1672-2124.2024.06.017
基于决策树模型的复方丹参喷雾剂治疗冠心病心绞痛的经济学评价
Economic Evaluation of Compound Danshen Spray in the Treatment of Angina Pectoris of Coronary Heart Disease Based on Decision Tree Model
摘要
Abstract
OBJECTIVE:To evaluate the pharmacoeconomics of compound Danshen spray in the treatment of angina pectoris of coronary heart disease,so as to provide reference for rational allocation of limited drug resources in health system.METHODS:Based on TreeAge Pro software,cost-effectiveness analysis of compound Danshen tablet vs.compound Danshen spray in the treatment of angina pectoris of coronary heart disease was performed.The cost parameters were derived from the Micron database and related literature.Meanwhile,the short-term economy of the two treatment schemes was studied according to a Meta-analysis,and the robustness of the results was verified through univariate sensitivity analysis and probabilistic sensitivity analysis.RESULTS:Basic results showed that compared with the compound Danshen tablet,compound Danshen spray in the treatment of patients with angina pectoris of coronary heart disease increased the electrocardiogram effective rate by 10%,6.06 yuan was needed.If the patients'willingness-to-pay was more than 6.06 yuan,compound Danshen spray was more economical,otherwise compound Danshen tablet was more economical.The sensitivity analysis had an impact on the results and verified the robustness of the results of the base analysis,which were consistent with the results of the base analysis.CONCLUSIONS:Based on the assumption that per capita disposable income(32189 yuan)in China in 2020 is the threshold of patients'willingness-to-pay,compared with compound Danshen tablet,compound Danshen spray is more economical in the treatment of angina pectoris of coronary heart disease.关键词
复方丹参喷雾剂/冠心病心绞痛/经济学评价Key words
Compound Danshen spray/Angina pectoris of coronary heart disease/Economic evaluation分类
医药卫生引用本文复制引用
胡聿尔,孙春全,谢雁鸣,黎元元,付常宽..基于决策树模型的复方丹参喷雾剂治疗冠心病心绞痛的经济学评价[J].中国医院用药评价与分析,2024,24(6):714-716,721,4.基金项目
国家重点研发计划项目(No.2018YFC1707400) （No.2018YFC1707400）
国家中医药管理局2021歧黄学者支持项目(No.国中医药人教函[2022]6号) （No.国中医药人教函[2022]6号）
谢雁鸣全国名老中医药专家传承工作室建设项目(No.国中医药人教函[2022]75号) （No.国中医药人教函[2022]75号）
中国中医科学院科技创新工程中医临床基础学科创新团队项目(No.CI2021B003) （No.CI2021B003）
